





Hodgkin's lymphoma was made. The patient was admitted under dermatology for evaluation. She underwent radiological and histopathological evaluation. Ultrasound and computerized axial tomography (CAT) scan revealed enlarged cervical, axillary and inguinal lymph nodes; multiple thyroid

and lung nodules, and thickened skin of the left lateral thoracic wall due to skin infiltration (Figs. 2-8). Her liver was enlarged at 18 cm and multiple small nodules were noted. Her skin biopsy showed perivascular, atypical mononuclear infiltrates into dermis forming aggregates. The atypical mononuclear cells were CD4<sup>+</sup> and CD8<sup>-</sup>, a large number of cells were CD 30<sup>+</sup> while CD68<sup>+</sup> cells were present in intervening dermal histiocytes. These findings were confirmatory for T cell lymphoma/MF. Histopathology of biopsied lymph node demonstrated large T cells (CD30<sup>+</sup>) consistent with blastic transformation of T cell lymphoma. A bone marrow biopsy showed no involvement.



**Fig. (2).** Thyroid ultrasound showing well defined hypoechoic lymph nodes posterior to the right lobe of the thyroid gland.



**Fig. (3).** Ultrasound of the neck showing an oval shaped hypoechoic cervical lymph node.


**Fig. (4).** CT image of the neck demonstrating large cervical lymph nodes on the right (arrow).



**Fig. (5).** CT axial image 1 of chest showing at level of arch of aorta multiple well defined lymph nodes in right lung of variable sizes.

**Fig. (6).** CT axial image of chest showing multiple well defined and variably sized lymph nodes in both lungs at the level of the heart.

The patient was taken over by the Oncology unit and received chemotherapy in combination of Cyclophosphamide, Rituximab, Doxorubicin and Vincristine.



**Fig. (7).** CT axial image of the liver at gastrohepatic level showing well defined and variably sized lymph nodes.



**Fig. (8).** CT axial image of the left lower chest showing left lateral chest wall thickening with thickening of the underlying muscles.

## DISCUSSION

T cell lymphoma is an indolent non-Hodgkin lymphoma of T-cell origin and MF is a variant of T cell lymphoma with characteristic skin involvement. This disorder differs from other primary T-cell lymphomas by its own unique clinical features and histopathology [1,2].

MF has no definite etiology [3] but hypothetical genetic involvement [4,5], chemicals and environmental exposure [6] human T cell virus type 1 (HTLV1) [7] and chromosomal abnormalities in the form of deletions and translocations have been implicated [8,9]. MF is a rare disease reported incidence is six cases per year per million [10]. The peak age of presentation is 55-60 years. *Mycosis fungoides* has a male

to female ratio of 2:1 and is more common in black than white patients [11].

Skin lesions are the most common presenting features which include generalized patches, plaques, and erythroderma like features. The promyelocytic type is a pre-diagnostic manifestation of MF which may prolong for decades until rapid progression to advanced disease. In the promyelocytic phase skin lesions are often misdiagnosed as psoriasis and non specific dermatitis due its resemblance to these conditions. The rate of misdiagnosis is very common at this stage [12-14]. Another uncommon feature is the mottled skin pigmentation known as poikiloderma [15]. The skin lesions are typically multiple and often more than 5 centimeters in size. These lesions tend to increase in size with disease progression [16].

Extradermal manifestation can involve any part of the body but the organs commonly involved are lymph nodes, lungs, liver, spleen peripheral blood and bone marrow [17-19].

Histopathologic hallmarks include epidermotropism or localization of abnormal T lymphocytes within the epidermis involving adhesion molecules soluble intercellular molecule 1 and 3 (sICAM1 and sICAM3). Aberrant cytokine production of helper T cells type 2 and low production of helper T cell type 1 cytokines are pathognomonic. This results in an impaired T cell response to mitogen which eventually leads to atypical progression of T cells [20-22].

The standard staging system for MF is based upon an evaluation of the skin (T), lymph nodes (N), visceral involvement (M), and blood (B). Therefore, the diagnostic strategy should include direct examination of the skin lesions followed by biopsy, complete blood count, blood chemistry, chest radiograph and computed tomography with or without positron emission tomography (PET). Molecular and immunohistopathologic studies are necessary to confirm the diagnosis in a patient with suspected skin lesions. The diagnostic criteria for MF is demonstrated in Table 1 [23]. The prognosis of patients with MF is variable. In those with extensive skin lesions and extradermal involvement the prognosis is poor. Treatment of MF depends upon the staging and includes localized topical therapy for early stages. The standard treatment of early lesions includes psoralens in association with UV-A irradiation (PUVA - psoralens and UVA), interferon  $\alpha$ -2a, retinoids, or a combination of these three modalities. Many new treatment protocols have been introduced for treatment of early MF including, among others, photodynamic therapy with 5-aminolaevulinic acid, new retinoids such as bexarotene. For advanced disease systemic retinoids, interferon, vorinostat, Denileukin, methotrexate, chlorambucil, and etoposide are also used in different combinations as per individual response. Bone marrow transplantation has also been used in certain cases. As a rule management of MF particularly in advance stage needs the specialized manage of a hematology-oncology service [24-26].

## CONCLUSION

This case report demonstrates that the presentation of occult conditions in DEM is quite frequent, and in such encounters prompt and speciality focused consultations can facilitate early diagnosis and should be considered by DEM to play active role in improving health care system.

**Table 1. Diagnostic Criteria of Mycosis Fungoids\***

Criteria	Scoring
<b>Clinical</b> <i>Basic:</i> Persistent and/or progressive patches/thin plaques 1. Non-sun exposed location 2. Size/shape variation 3. Poikiloderma	2 points for basic criteria and two additional criteria 1 point for basic criteria and one additional criterion
<b>Histopathological:</b> <i>Basic:</i> Superficial lymphoid infiltrate <i>Additional:</i> 1. Epidermotropism without spongiosis 2. Lymphoid atypia	2 points for basic criteria and two additional criteria 1 point for basic criteria and one additional criterion
Molecular biology: Clonal T cell receptor (TCR) gene rearrangement	1 point for clonality
Immunopathologic: 1. <50 percent CD2+, CD3+, and/or CD5+ T-cells 2. <10 percent CD7+ T cells 3. Epidermal/dermal discordance of CD2, CD3, CD5, or CD7	1 point for one or more criteria

\*A total of 4 points is required for the diagnosis of MF based on any combination of points from the clinical, histopathologic, molecular biological, and immunopathologic criteria. Adapted by ref. [23]: Pimpinelli, N, Olsen, EA, Santucci, M, *et al.*, Defining early mycosis fungoides. *J Am Acad Dermatol* 2005; 53:1053.

## CONFLICT OF INTEREST

None declared.

## ACKNOWLEDGEMENT

None declared.

## REFERENCES

- [1] Siegel RS, Pandolfino T, Guitart J, *et al.* Primary cutaneous T-cell lymphoma: review and current concepts. *J Clin Oncol* 2000; 18(4): 2908-25.
- [2] Jaffe ES, Harris NL, Stein H. World health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon 2001.
- [3] Whittaker S. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). *Semin Oncol* 2006; 33(1Suppl 3): S3-6.
- [4] Van Doorn R, Zoutman WH, Dijkman R, *et al.* Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. *J Clin Oncol* 2005; 23(17): 3886-96.
- [5] Shin J, Monti S, Aires DJ, *et al.* Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. *Blood* 2007; 110(8): 3015-27.
- [6] Whittemore AS, Holly EA, Lee IM, *et al.* Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. *J Natl Cancer Inst* 1989; 81(20): 1560-7.
- [7] Ghosh SK, Abrams JT, Terunuma H, *et al.* Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma. *Blood* 1994; 84(8): 2663-71.
- [8] Thangavelu M, Finn WG, Yelavarthi KK, *et al.* Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome. *Blood* 1997; 89(9): 3371-7.
- [9] Karenko L, Hyytinen E, Sarna S, *et al.* Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. *J Invest Dermatol* 1997; 108(1): 22-9.
- [10] Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. *Arch Dermatol* 2007; 143(7): 854-9.
- [11] Bradford PT, Devesa SS, Anderson WF, *et al.* Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. *Blood* 2009; 113(21): 5064-73.
- [12] Demierre MF, Gan S, Jones J, *et al.* Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. *Cancer* 2006; 107(10): 2504-11.
- [13] Zackheim HS, Jones C, Leboit PE, *et al.* Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality. *J Am Acad Dermatol* 2003; 49(4): 620-3.
- [14] Zackheim HS, McCalmont TH. *Mycosis fungoides*: The great imitator. *J Am Acad Dermatol* 2002; 47(6): 914-8.
- [15] Kodama K, Fink-Puches R, Massone C, *et al.* Papular mycosis fungoides: a new clinical variant of early mycosis fungoides. *J Am Acad Dermatol* 2005; 52(4): 694-8.
- [16] Kim YH, Chow S, Varghese A, *et al.* Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) *Mycosis fungoides*. *Arch Dermatol* 1999; 135(1): 26-32.
- [17] Vonderheid EC, Diamond LW, Van Vloten WA, *et al.* Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage. *Cancer* 1994; 73(1): 207-18.
- [18] Baser S, Onn A, Lin E, *et al.* Pulmonary manifestations in patients with cutaneous T-cell lymphomas. *Cancer* 2007; 109(80): 1550-5.
- [19] Hoppe RT, Wood GS, Abel EA. *Mycosis fungoides* and the Sezary syndrome: pathology, staging, and treatment. *Curr Probl Cancer* 1990; 14(60): 293-371.
- [20] Epstein EH Jr, Levin DL, Croft JD Jr, *et al.* *Mycosis fungoides*. survival, prognostic features, response to therapy, and autopsy findings. *Medicine (Baltimore)* 1972; 51(1): 61-72.
- [21] Girardi M, Heald PW, Wilson LD. The pathogenesis of *Mycosis fungoides*. *N Engl J Med* 2004; 350(19): 1978-88.
- [22] Lopez-Lerma I, Estrach MT. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in *Mycosis fungoides* and sezary syndrome. *J Am Acad Dermatol* 2009; 61(2): 263-70.

- [23] Pimpinelli N, Olsen EA, Santucci M, *et al.* Defining early *Mycosis fungoides*. *J Am Acad Dermatol* 2005; 53(6): 1053-63.
- [24] Case DJ. Combination chemotherapy for *Mycosis fungoides* with cyclophosphamide, vincristine, methotrexate, and prednisone. *Am J Clin Oncol* 1984; 7(5): 453-555.
- [25] Duarte RF, Schmitz N, Servitje O, *et al.* Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. *Bone Marrow Transplant* 2008; 41(7): 597-604.
- [26] Jones GW, Kacinski BM, Wilson LD, *et al.* Total skin electron radiation in the management of mycosis fungoides: Consensus of the european organization for research and treatment of cancer (EORTC) cutaneous lymphoma project group. *J Am Acad Dermatol* 2002; 47(3): 364-70.

---

Received: February 23, 2011

Revised: October 28, 2011

Accepted: October 30, 2011

© Shujaa and Suriya; Licensee *Bentham Open*.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.